ArticleNeurobiology of aging2020
Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.
Open access · greenAbstract read
In one paragraph
Article in Neurobiology of aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Pooled it
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- The hippocampal sparing subtype of Alzheimer's disease assessed in neuropathology and in vivo tau positron emission tomography: a systematic review.Acta neuropathologica communications · 2022Pooled it
- Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Article
- Reliability and modeling of digital histological measurements in Alzheimer's disease neuropathologic change and Lewy body disease.Journal of neuropathology and experimental neurology · 2025Article
- Data-driven characterization of distinct cognitive subtypes in Parkinson's disease dementia.NPJ Parkinson's disease · 2025Article
- Article
- Lewy body co-pathology in Alzheimer's disease and primary age-related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Sex differences for clinical correlates of substantia nigra neuron loss in people with Lewy body pathology.Biology of sex differences · 2024Article
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.International journal of molecular sciences · 2023Review
- Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies.Journal of neuropathology and experimental neurology · 2022Article
- α-Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α-Synuclein in the Context of Co-Pathology and Non-LBD Diagnoses.Annals of neurology · 2022Article
- Morphological basis of Parkinson disease-associated cognitive impairment: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease.Journal of Parkinson's disease · 2022Article
- LateralizedAlzheimer's & dementia (New York, N. Y.) · 2022Article
- Imaging tau burden in dementia with Lewy bodies using [Neurobiology of aging · 2021Article
- Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
David G CoughlinDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Digital Neuropathology Laboratory, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Lewy Body Disease Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Jeffrey S PhillipsDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Emily RollDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Claire PetersonDigital Neuropathology Laboratory, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Rebecca LobrovichDigital Neuropathology Laboratory, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Katya RascovskyDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Molly UngradyDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
David A WolkDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Sandhitsu DasDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Daniel WeintraubDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Michael J. Crescenz VA Medical Center, Parkinson's Disease Research, Education, and Clinical Center, Philadelphia, PA, USA.
Edward B LeeAlzheimer's Disease Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
John Q TrojanowskiDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Center for Neurodegenerative Disease Research, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Leslie M ShawDepartment of Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Sanjeev VaishnaviDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Lewy Body Disease Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Andrew SiderowfDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Lewy Body Disease Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Ilya M NasrallahDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
David J IrwinDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Digital Neuropathology Laboratory, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Lewy Body Disease Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Corey T McMillanDepartment of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Electronic address: mcmillac@pennmedicine.upenn.edu.
Alzheimer’s Disease Neuroimaging Initiative
Hospital of the University of Pennsylvania · USUniversity of Pennsylvania · US
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7MAlzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MTransgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3MUPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1MUCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Steven Dyal Edland · 2019 to 2026
$34.9MProject IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9MUnderstanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8MProject IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2019 to 2023
$18.1MNRSA Training CoreTL1TR001880 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$10.0MSpreading Tau Pathology in Non-Amnestic Alzheimer's DiseaseR01AG054519 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jeffrey S Phillips · 2018 to 2026
$7.4MMicroscopic and Large-Scale Networks of Molecular Pathology in Frontotemporal Lobar DegenerationR01NS109260 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI IRWIN, DAVID JOHN · 2019 to 2023
$3.8MIdentification of Endophenotypes in the Behavioral-Variant of Frontotemporal DemeK23NS088341 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI IRWIN, DAVID JOHN · 2014 to 2018
$836kCIHRNCATS NIH HHS TL1 TR001880NIA NIH HHS K01 AG061277NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG054519NIA NIH HHS R56 AG058732NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG062418NINDS NIH HHS K23 NS088341NINDS NIH HHS P50 NS053488NINDS NIH HHS R01 NS109260
Abstract
We compared regional retention of
Indexed as
Alzheimer DiseaseAutopsyBiomarkersCarbolinesCognitionFemaleHumansLewy Body DiseaseMalePositron-Emission TomographySeverity of Illness Indextau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleBiomarkersCarbolinestau ProteinsCognitionCSFLewy body diseasesNeuropathologyPET imagingTau
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.